Patent intelligence · US
US 10751332
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
Patent details — US 10751332
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 25, 2020
- Expiration
- Aug 20, 2040
- Applicant
- Asana BioSciences, LLC
- Claims
- 7
- CPC classes
- A61K, A61K31/443, A61K31/4439, A61K31/444
Quick answer
US 10751332 (Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer) is held by Asana BioSciences, LLC. Status: granted. Granted Aug 25, 2020. Expires Aug 20, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Asana BioSciences, LLC
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K31/443, A61K31/4439, A61K31/444, A61K31/506, A61K31/5377
More from Asana BioSciences, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 10751332?
US 10751332 (Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer) is held by Asana BioSciences, LLC. Status: granted. Granted Aug 25, 2020. Expires Aug 20, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10751332?
Asana BioSciences, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 10751332 expire?
Our index shows an expiration date of Aug 20, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.